salvage treatment

PROCEDURE2 trials

Sponsors

University Hospital, Ghent, Yanhong Deng

Conditions

Neuroendocrine TumorsProstate CancerRectal Neoplasms

Phase 2

Non-systemic Treatment for Patients With Low-volume Metastatic Prostate Cancer

CompletedNCT01558427

University Hospital, GhentProstate Cancer

Start: 2012-08-01End: 2023-08-15Updated: 2023-09-05

Unknown Phase

Clinical Relevance of the Salvage Treatment for Colorectal Neuroendocrine Tumors

CompletedNCT06143605

Yanhong DengNeuroendocrine Tumors, Rectal Neoplasms

Start: 2013-01-30End: 2023-09-30Updated: 2023-11-22

Related Papers

World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): An analysis from the X-MET collaboration.

Journal of Clinical Oncology2025-02-1016 citations

Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): Five-year results of a randomized phase II trial.

Journal of Clinical Oncology2020-02-19148 citations

Estimating the incidence of oligorecurrent and potentially salvageable prostate cancer on 18F-Choline PET-CT: Screening phase of the STOMP randomized phase II trial.

Journal of Clinical Oncology2017-02-205 citations

OLIGOPELVIS – GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer

BMC Cancer2015-09-2545 citations

Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial

BMC Cancer2014-09-15129 citations